Total Payments
$818,485
2024 Payments
$107,319
Companies
26
Transactions
393
Medicare Patients
6,934
Medicare Billing
$607,630
Payment Breakdown by Category
Consulting$696,650 (85.1%)
Research$53,348 (6.5%)
Travel$36,950 (4.5%)
Other$22,498 (2.7%)
Food & Beverage$9,039 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $696,650 | 151 | 85.1% |
| Unspecified | $53,348 | 36 | 6.5% |
| Travel and Lodging | $36,950 | 81 | 4.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,998 | 6 | 2.2% |
| Food and Beverage | $9,039 | 117 | 1.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,500 | 2 | 0.5% |
Payments by Type
General
$765,137
357 transactions
Research
$53,348
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $130,195 | 52 | $0 (2023) |
| Alcon Research LLC | $119,012 | 71 | $0 (2021) |
| Novartis Pharma AG | $116,092 | 6 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $100,748 | 34 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $58,206 | 31 | $0 (2024) |
| Allergan, Inc. | $54,510 | 61 | $0 (2021) |
| F. Hoffmann-La Roche AG | $53,919 | 22 | $0 (2024) |
| Alcon Vision LLC | $34,876 | 22 | $0 (2024) |
| Astellas Pharma Global Development | $26,500 | 2 | $0 (2024) |
| ThromboGenics, Inc. | $24,006 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107,319 | 55 | Boehringer Ingelheim International GmbH ($19,975) |
| 2023 | $47,939 | 22 | Astellas Pharma Global Development ($14,500) |
| 2022 | $235,049 | 33 | Novartis Pharma AG ($111,725) |
| 2021 | $94,945 | 19 | Novartis Pharmaceuticals Corporation ($66,726) |
| 2020 | $85,604 | 50 | Regeneron Pharmaceuticals, Inc. ($32,517) |
| 2019 | $57,371 | 65 | Allergan Inc. ($30,064) |
| 2018 | $78,263 | 76 | Alcon Research Ltd ($38,643) |
| 2017 | $111,995 | 73 | Alcon Research Ltd ($62,697) |
All Payment Transactions
393 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Beaver-Visitec International, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: RARE DISEASES | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| Category: RARE DISEASES | ||||||
| 12/05/2024 | Alcon Vision LLC | Constellation (Device) | Travel and Lodging | Cash or cash equivalent | $46.00 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | Cash or cash equivalent | $36.44 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | Cash or cash equivalent | $26.01 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | Cash or cash equivalent | $8.62 | General |
| Category: Ophthalmology | ||||||
| 11/29/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/29/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/29/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/21/2024 | Alcon Vision LLC | Constellation (Device) | Consulting Fee | Cash or cash equivalent | $17,500.00 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 11/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration | Astellas Pharma Global Development | $14,500 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $6,188 | 7 |
| Publication support research related | Novartis Pharma AG | $4,367 | 3 |
| A TWO YEAR RANDOMIZED DOUBLE MASKED MULTICENTER THREE ARM STUDY COMPARING THE SAFETY AND EFFICACY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATIONGE RELATED MACULAR DEGENERATION | Novartis Pharmaceuticals Corporation | $3,112 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH BEOVU RESEARCH | Novartis Pharmaceuticals Corporation | $3,007 | 1 |
| CRTH258A2301 | Novartis Pharmaceuticals Corporation | $2,711 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, TWO-ARM STUDY COMPARING THE EFFICACY AND SAFETY OF ESBA1008 VERSUS EYLEA IN SUBJECTS WITH EXUDATIVE AGE RELATED MACULAR DEGENERATION | Novartis Pharmaceuticals Corporation | $2,182 | 1 |
| BRO-MS-95789 LONGITUDINAL ASSESSMENT OF ELLIPSOID ZONE SUBRETINAL HYPERREFLECTIVE MATERIAL & SUB-RPE DISEASE FEATURES IN NEOVASCULAR AMD IN THE OSPREY | NOVARTIS PHARMACEUTICALS CORPORATION | $2,045 | 1 |
| CLR-3726/BRO-MS -98408 THE IMPACT OF FLUID VOLATILITY ON SUBRETINAL HYPERREFLECTIVE MATERIAL AND ELLIPSOID ZONE INTEGRITY IN NAMD IN THE OSPREY STUDY | NOVARTIS PHARMACEUTICALS CORPORATION | $2,045 | 1 |
| BRO-MS -98072 LONGITUDINAL HIGHER-ORDER OCT ASSESSMENT OF QUANTITATIVE FLUID DYNAMICS AND THE TOTAL RETINAL FLUID INDEX IN NEOVASCULAR AMD | NOVARTIS PHARMACEUTICALS CORPORATION | $1,875 | 1 |
| BRO-MS-95913 LONGITUDINAL HIGHER-ORDER OCT ASSESSMENT OF MACULAR FLUID DYNAMICS AND RETINAL FLUID INDEX IN NEOVASCULAR AMD FROM THE OSPREY STUDY | NOVARTIS PHARMACEUTICALS CORPORATION | $1,875 | 1 |
| A DOUBLE- MASKED, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL ADMINISTRATION OF VEGF TRAP-EYE IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $1,315 | 5 |
| BRO-OP -92977 LONGITUDINAL DYNAMICS IN OUTER RETINAL INTEGRITY IN NAMD: HIGHER-ORDER OCT FEATURE EXTRACTION AND INSIGHTS FROM THE OSPREY TRIAL | NOVARTIS PHARMACEUTICALS CORPORATION | $1,200 | 1 |
| BRO-OP -99111 FLUID COMPARTMENT VOLATILITY AND DYNAMICS IN NEOVASCULAR AMD TREATED WITH ANTI-VEGF THERAPY: IMPLICATIONS FOR OUTER RETINAL INTEGRITY | NOVARTIS PHARMACEUTICALS CORPORATION | $1,000 | 1 |
| Longitudinal Quantitative Ultra-Widefield Fluorescein Angiography Leakage Dynamics in Patients With Uveitic Macular Edema Following Intravitreal Anti?IL-6 Therapy With Vamikibart | F. Hoffmann-La Roche AG | $994.00 | 1 |
| Volumetric Fluid Dynamics Using Machine-Learning Augmented Analysis in Patients With Uveitic Macular Edema Receiving Vamikibart in the DOVETAIL Study | F. Hoffmann-La Roche AG | $994.00 | 1 |
| BRO-OP -98871 FLLUID BURDEN AND OUTER RETINAL INTEGRITY DYNAMICS IN NAMD: HIGHER-ORDER OCT ASSESSMENTS FROM THE OSPREY TRIAL | NOVARTIS PHARMACEUTICALS CORPORATION | $750.00 | 1 |
| BRO-PO -93997 CHANGES IN SUB-RETINAL PIGMENT EPITHELIUM VOLUME IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH TREATMENT: OSPREY TRIAL DATA SET | NOVARTIS PHARMACEUTICALS CORPORATION | $750.00 | 1 |
| BRO-OP-93996 RETINAL FLUID INDEX, A NOVEL OPTICAL COHERENCE TOMOGRAPHY PARAMETER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: OSPREY TRIAL DATA | NOVARTIS PHARMACEUTICALS CORPORATION | $600.00 | 1 |
| Cleveland Clinic DOVETAIL UME advanced retinal fluid analysis | F. Hoffmann-La Roche AG | $475.36 | 1 |
| Cleveland Clinic DOVETAIL UME vascular leakage analysis | F. Hoffmann-La Roche AG | $475.36 | 1 |
| BRO-AB-97968 FLUID COMPARTMENT VOLATILITY AND DYNAMICS IN NEOVASCULAR AMD TREATED WITH ANTI-VEGF THERAPY: IMPLICATIONS FOR OUTER RETINAL INTEGRITY | NOVARTIS PHARMACEUTICALS CORPORATION | $475.00 | 1 |
| BRO-AB -93999 FLUID BURDEN AND OUTER RETINAL INTEGRITY DYNAMICS IN NAMD: HIGHER-ORDER OCT ASSESSMENTS FROM THE OSPREY TRIAL | NOVARTIS PHARMACEUTICALS CORPORATION | $356.00 | 1 |
| A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema | Regeneron Pharmaceuticals, Inc. | $56.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 1,770 | 3,792 | $1.5M | $150,493 |
| 2022 | 9 | 1,858 | 4,017 | $1.4M | $160,355 |
| 2021 | 9 | 1,797 | 3,984 | $1.4M | $161,613 |
| 2020 | 6 | 1,509 | 3,219 | $1.2M | $135,170 |
Total Patients
6,934
Total Services
15,012
Medicare Billing
$607,630
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 67028 | Injection of drug into eye | Office | 2023 | 122 | 552 | $464,889 | $37,583 | 8.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 452 | 716 | $284,252 | $35,820 | 12.6% |
| 67028 | Injection of drug into eye | Facility | 2023 | 80 | 336 | $276,186 | $22,441 | 8.1% |
| 92014 | Established patient complete exam of visual system | Facility | 2023 | 265 | 427 | $169,519 | $21,582 | 12.7% |
| 92134 | Imaging of retina | Office | 2023 | 458 | 994 | $169,974 | $16,689 | 9.8% |
| 92134 | Imaging of retina | Facility | 2023 | 289 | 659 | $112,689 | $11,145 | 9.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 38 | $10,336 | $1,721 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 29 | 30 | $8,160 | $1,457 | 17.9% |
| 92004 | New patient complete exam of visual system | Facility | 2023 | 14 | 14 | $7,672 | $909.12 | 11.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 12 | $5,028 | $699.93 | 13.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2023 | 14 | 14 | $3,850 | $445.76 | 11.6% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 428 | 712 | $282,664 | $35,949 | 12.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 103 | 494 | $366,606 | $33,488 | 9.1% |
| 92014 | Established patient complete exam of visual system | Facility | 2022 | 304 | 533 | $211,601 | $27,579 | 13.0% |
| 67028 | Injection of drug into eye | Facility | 2022 | 89 | 362 | $264,771 | $24,346 | 9.2% |
| 92134 | Imaging of retina | Office | 2022 | 439 | 979 | $151,745 | $16,777 | 11.1% |
| 92134 | Imaging of retina | Facility | 2022 | 330 | 763 | $118,265 | $13,114 | 11.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 61 | $15,067 | $3,054 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 45 | 49 | $12,103 | $2,321 | 19.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 13 | $6,981 | $1,249 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 17 | $6,477 | $1,151 | 17.8% |
| 92004 | New patient complete exam of visual system | Facility | 2022 | 12 | 12 | $6,576 | $810.69 | 12.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2022 | 11 | 11 | $2,750 | $354.49 | 12.9% |
| 92250 | Photography of the retina | Office | 2022 | 11 | 11 | $1,463 | $162.33 | 11.1% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 444 | 823 | $326,731 | $44,441 | 13.6% |
About Dr. Justis Ehlers, M.D
Dr. Justis Ehlers, M.D is a Ophthalmology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1235346248.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Justis Ehlers, M.D has received a total of $818,485 in payments from pharmaceutical and medical device companies, with $107,319 received in 2024. These payments were reported across 393 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($696,650).
As a Medicare-enrolled provider, Ehlers has provided services to 6,934 Medicare beneficiaries, totaling 15,012 services with total Medicare billing of $607,630. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Cleveland, OH
- Active Since 05/17/2007
- Last Updated 01/09/2012
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1235346248
Products in Payments
- BEOVU (Drug) $220,806
- Constellation (Device) $76,451
- EYLEA (Biological) $54,979
- Izervay (Drug) $41,500
- NGENUITY (Device) $38,605
- Non-Covered Product (Drug) $25,968
- Jetrea (Drug) $24,006
- Luxor (Device) $20,367
- OZURDEX (Drug) $19,752
- AcrySof (Device) $13,063
- Lucentis (Biological) $11,372
- RESCAN 700 (Device) $8,017
- BROLUCIZUMAB (Drug) $7,081
- ARTEVO 800 (Device) $5,940
- VEOPOZ (Biological) $3,290
- EYP-1901 $1,388
- SYFOVRE (Drug) $1,086
- Syfovre (Drug) $543.00
- EYLEA AFLIBERCEPT INJECTION (Biological) $502.91
- OPMI Lumera (Device) $201.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Cleveland
Peter Kaiser, Md, MD
Ophthalmology — Payments: $1.7M
Ophthalmology $1.7M
William Wiley, M.d, M.D
Ophthalmology — Payments: $775,102
Ophthalmology $775,102
Sunil Srivastava, Md, MD
Ophthalmology — Payments: $668,061
Ophthalmology $668,061
Yasha Modi, M.d, M.D
Ophthalmology — Payments: $244,095
Ophthalmology $244,095
Dr. Douglas Rhee, M.d, M.D
Ophthalmology — Payments: $162,043
Ophthalmology $162,043
Faruk Orge, Md, MD
Ophthalmology — Payments: $156,811
Ophthalmology $156,811